Ukukhupha ibhaktheriya kunokudlala indima kwisifo sengqondo se-bladder (IBS). Ukuba ufumana i-IBS, ngamanye amaxesha ungacinga ukuba kukho imfazwe ngaphakathi emzimbeni wakho. Ewe, uphando olutsha lwe-IBS lubonisa ukuba unokuya kwizinto ezithile.
Isistim sakho se-intestinal sigcwele iibhiliyoni zeebhaktheriya zazo zonke iintlobo ezahlukeneyo; zonke iibhaktheriya zibizwa ngokuba yi- flora .
Kwimeko yempilo efanelekileyo, zonke ezi bhaktheriya zidlala kakuhle. Ngelishwa, kukho amaxesha apho i-balance of the flora igxininisekile, i-state eyaziwa ngokuthi ngamathumbu e-intestinal dysbiosis , okubangelwa iimpawu zesisu esisemnandi. Oku kunokwenzeka ngezizathu ezahlukahlukeneyo, ezinjenge- gastroenteritis (intsholongwane yesisu) okanye njengomphumo we-antibiotics. Kwihlabathi lophando , kukho izikhokelo ezintsha ukuba ukuphazamiseka okuqhubekayo kwintlambo yamanzi kungabangela inzondo ukuba uyazi njenge-IBS. Ezi nkcazelo zivela kwiindawo ezine ezidibeneyo:
IBS-I-Post-Infectious IBS
Ubungqina buqala ukunyuka okubonisa ukuba i-IBS ikhula kwabanye abantu emva kokusuleleka kwintsholongwane ebhaktheriya kwinkqubo yokutya . Uphononongo lwabantu abanoosuleleko lufumene ukuba malunga nama-25% baya kuqhubeka befumana iimpawu ze-GI ezingathandekiyo emva kweenyanga ezintandathu emva kokugula kokuqala.
Okuphazamisayo ngakumbi kukufumanisa ukuba omnye kwabafundi abayi-10 abafumana ukusuleleka kwe-GI ekhuselekileyo baya kugqiba ngengxaki eqhubekayo ebizwa ngokuba yi-IBS. Kule meko, kukho ukuchongwa kwekhonkco ecacileyo kwindawo yokugula yokugaya, ihlelwa njenge-IBS-IBS-PI.
Uphando lwebhabhi lunikeza iinkcukacha ezithile malunga ne-IBS-PI. Ukusebenzisa inkqubo apho izicubu zecandelo le-rectum zixutywa, abaphandi bafumene iiseli ezinxulumene nokuvuvukala kunye ne-serotonin kwiimpawu ezixhamlayo zabantu abaphuhlisa i-IBS. Oku kunika ubungqina obuninzi bendima yokuvuvukala kunye nokuxhunywa kweengqondo-ntlungu ekugcinweni kweempawu ze-IBS.
Probiotics
Ubungqina obuninzi bokubandakanya ibhaktiriya kwi-IBS buvela ekusebenzeni kweprobiotics ekunciphiseni iimpawu. Iiprobiotics ziyaziwa ngokuba yi-"bhuti" kuba zicinga ukuba zinceda kwimpilo yesondlo sakho. Nangona uninzi lweengxelo zonyango lwe-probiotics ze-IBS zivela kwiingxelo ze-anecdotal, uhlobo oluthile lwe-probiotic, i-Bifidobacterium infantis iye yaboniswa kwikliniki ekunciphiseni iimpawu ze-IBS. Kucingelwa ukuba ukuthatha i-probiotics supplement kunceda ukubuyisela iibhaktheriya ngaphakathi kwintlambo yamanzi ukuya kwimeko ephezulu yokulinganisela.
Ukugqithiswa kweBestinal Intestinal Overgrowth (SIBO)
Ukugqithisa kwebhakterth encinci ye-intestinal (SIBO) yimeko apho kukho inani elingaqhelekanga leebhaktheriya emathunjini amancinci. Ingcamango entsha kunye neyongqinelanayo ifuna ukuchonga iSIBO njengesizathu esibalulekileyo se-IBS .
Abaxhasi be-SIBO i-theory bakholelwa ukuba i-SIBO ilandele i-symptom ye-bloating, utshintsho kwi- motility ebenokubangela ukurhoxiswa nokuqhawulwa , kunye ne- visceral hypersensitivity ebonwe kwizigulane ze-IBS.
I-SIBO ixilongwa ngokuqhelekileyo isebenzisa uvavanyo olulinganisa umlinganiselo we-hydrogen ekuphefumlweni emva kokungenisa iziphuzo ezinomthamo we-lactulose. I-Lactulose yishukela engagqithwanga ngemizimba yethu, ngoko ityutywa yi-bhakteria ngaphakathi kwenkqubo yamathumbu. Ukuba inani lokuphefumla i-hydrogen liphakamileyo ixesha elifutshane emva kokusela isisombululo se lactulose, kukholelwa ukuba ibonisa izinga eliphezulu leebhaktheriya ngaphakathi emathunjini amancinci.
Ingxabano ixhomekeke kwiingxelo eziphikisanayo malunga nokuchaneka kovavanyo lokuphefumula kwe-hydrogen, kunye neengxelo eziphikisanayo malunga nokuba ziphi izigulane ze-IBS ezivelisa umphumo ophezulu wokuvavanya. Njengokuba kunjalo ngoku, isiphetho ngaphakathi kwiphando lophando lwe-IBS kukuba i-SIBO ingafanelekile kwi-subset ethile yezilwanyana ze-IBS.
Antibiotics
Olunye ummandla wophando olubonisa ukuba ama-bacteria asegulini athatha inxaxheba kwi-IBS ifumaneka kwi-theory ye-SIBO kunye nokusetyenziswa ngempumelelo kwee-antibiotics ezithile njengonyango lwe-IBS. Kusetyenziswa ii-antibiotics ezimbini, i-Rifaximin ne-Neomycin, kunye neRifaximin ebonisa umda omncinci ngokusebenza. Ezi antibiotics ziye zonyulwa ngenxa yokuba zingabandakanyi esiswini, kwaye ngoko kucatshangelwa ukuba ziyakwazi ukuhlasela nayiphi na i-bhakteria elele ngaphakathi emathunjini amancinci. Izifundo zibonise ukuba ezi antibiotics zibangele ukuphucula uphawu oluphawulekayo kwaye zinokudityaniswa neenguqu ezintle kwiimvavanyo zokuphefumula kwe-hydrogen. Ukuhlaselwa ekusebenziseni i-antibiotics kuthethwa ngeendleko zabo eziphezulu kunye nenkxalabo yokuba babe negalelo ekuphuhliseni iifom ezinqandekayo zebhaktheriya. I-antibiotics yayiza kubhalwa kuphela kumntu apho uvavanyo lwe-hydrogen lokuphefumula lubonisa ubukho be-bacterial overgrowth emathunjini amancinci.
> Imithombo:
> Drossman, D. "Unyango lwe-Bacterial Overgrowth kwi-Irritable Bowel Syndrome" Iingxelo zeMithi yoNyaka ka-2006 2006 145: 626-628.
> Fumi, A. & Trexler, K. "I-Rifaximin Treatment of Symptoms of Irritable Bowel Syndrome" I-Annals ye-Pharmacotherapy 2008 42: 408-412.
> UGarcia Rodriguez, uL. & Ruigomez, A. "Ingozi eyongezelelekileyo yokugulisa isifo sengqondo emva kwe-bacterium gastroenteritis: isifundo seqela" BMJ 1999 318: 565-566.
> Gwee, K., Collins, S., Funda, N., Rajnakova, A., Deng, Y., Graham, J., McKendrick, M. & Moochala, S. "Ukunyuka kwe-interleukin 1 fumana i-post-infirmous irritable bowel syndrome echasayo Ingqungquthela ka- 2003 52: 523-526.
> Lin, H. "Inqwaba yeBhakterial Overstrowth" I- Journal ye-American Medical Association 2004 292: 852-858.
> O'Mahony, L., McCarthy, J., Kelly, P., Hurley, G., Luo, F., Chen, K., O'Sullivan, G., Kiely, B., Collins, J., I-Shanahan, F. & Quigley, E. "I-Lactobacillus kunye ne-bifidobacterium kwisifo sengqondo sesifo esilumkileyo: Iimpawu zokubonakalisa kunye nolwalamano lwe-cytokine" I- Gastroenterology 2005 128: 541-551.
> Pimental, M., Park, S., Mirocha, J., Kane, S., & Kong, Y. "I-Impact ye-Nonabsorbed Oral Antibiotic (Rifaximin) kwiSimpawu ze-Irritable Bowel Syndrome" (2006) 145: 557-563.
> Sharara, A. Aoun, A., Abdul-Baki, H., Mounzer, R., Sidani, S. & ElHaii "I-Rifaximin i-Double-Blind Placebo-Controled Trial Trial". I-Gastroenterology (2006) 101: 326.
> Spiller, R. "I-post-infectious irritable bowel syndrome" I- Gastroenterology 2003 124: 1662-1671.